How Much Does Vyleesi (Bremelanotide) Cost in Idaho in 2026?

Brand-Name Vyleesi Pricing at Idaho Pharmacies

The wholesale acquisition cost set by Palatin Technologies places Vyleesi at approximately $1,200 per month for on-demand use. That figure is consistent across major Idaho retail chains, including Albertsons, Walgreens, and Rite Aid locations in Boise, Idaho Falls, and Coeur d'Alene. Cash-pay pricing at independent pharmacies tracks very close to the same number because the drug has no generic equivalent and only one manufacturer.

Vyleesi is dispensed as a pre-filled, single-dose autoinjector containing 1.75 mg of bremelanotide. The FDA-approved labeling specifies subcutaneous injection at least 45 minutes before anticipated sexual activity, with a ceiling of one dose per 24 hours and eight doses per calendar month [1]. A patient using the drug four times per month would spend roughly $300 per use at cash-pay rates. Eight-dose months push the effective per-dose cost to about $150.

Price variability across Idaho pharmacies is minimal. GoodRx and RxSaver coupons occasionally shave 5 to 10 percent off the retail price, but these discounts are inconsistent and typically drop the out-of-pocket number to between $1,050 and $1,150 rather than producing a meaningful reduction.

Idaho Medicaid Does Not Cover Vyleesi

Idaho Medicaid excludes Vyleesi from its preferred drug list. The state has not added bremelanotide to its formulary, and prior authorization pathways for coverage exceptions are not established for this drug class. Patients enrolled in Idaho Medicaid who have a diagnosis of HSDD must explore alternatives or pay out of pocket.

This gap is not unique to Idaho. A 2023 analysis of Medicaid formularies across all 50 states found that fewer than 10 state Medicaid programs provided any coverage pathway for bremelanotide [2]. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recognized pharmacotherapy for HSDD as clinically appropriate in selected patients, but Medicaid programs have been slow to incorporate newer agents [3].

For Idaho Medicaid enrollees, compounded bremelanotide (discussed below) is the most practical cost-reduction option. A second alternative is flibanserin (Addyi), a daily oral pill with a different mechanism, though it also lacks Medicaid coverage in Idaho and carries its own cost and adherence considerations.

Private Insurance Coverage in Idaho

Commercial plans in Idaho vary widely on Vyleesi. Blue Cross of Idaho, Regence BlueShield of Idaho, and SelectHealth (the three largest carriers in the state) each handle bremelanotide differently. Some plans place it on a specialty tier with a copay of $100 to $250 per fill after prior authorization. Others exclude it outright.

Prior authorization criteria, where they exist, typically mirror the FDA label: documented HSDD diagnosis in a premenopausal woman, failure of or contraindication to non-pharmacologic interventions, and prescribing by or in consultation with a clinician experienced in sexual medicine. Plans that do cover the drug frequently require step therapy showing that flibanserin was tried first.

Dr. Sheryl Kingsberg, a clinical psychologist at University Hospitals Cleveland Medical Center and co-investigator on the RECONNECT trials, has noted: "Access barriers for HSDD treatments remain disproportionate relative to the clinical evidence supporting them. The prior authorization burden for bremelanotide is substantially higher than for comparably supported therapies in other specialties" [4].

Patients should request a formulary exception letter from their prescriber if a plan denies coverage. Idaho's Department of Insurance allows external review of formulary exclusion decisions, and some patients have obtained coverage through that appeals process.

Compounded Bremelanotide in Idaho: Legal, Available, and Cheaper

Compounded bremelanotide is legal in Idaho when dispensed by a licensed 503A compounding pharmacy with a valid patient-specific prescription. The cost is approximately $140 per month, representing an 88% reduction compared to brand Vyleesi.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients when a prescriber determines that a commercially available product does not meet a patient's medical needs [5]. Idaho's Board of Pharmacy regulates these pharmacies under IDAPA 27.01.01, and the state does not impose additional restrictions on compounding that would prevent bremelanotide preparation.

A few practical points for Idaho patients considering compounded bremelanotide:

The compound is typically prepared as a subcutaneous injectable in the same 1.75 mg dose as the brand product, though some pharmacies offer dose flexibility under prescriber direction. The autoinjector device is proprietary to Palatin Technologies and is not replicated; compounded versions use standard insulin-style syringes.

Patients should confirm that their compounding pharmacy holds a current Idaho Board of Pharmacy license and operates under 503A (patient-specific) rather than 503B (outsourcing facility) rules, as the regulatory framework and pricing differ. Several telehealth platforms that serve Idaho patients work with 503A pharmacies that ship compounded bremelanotide directly.

The FDA's guidance on compounding emphasizes that compounded drugs are not FDA-approved and do not undergo the same premarket testing as manufactured products [6]. Patients should discuss the risk-benefit profile with their prescriber.

Palatin Technologies Savings Card and Copay Assistance

Palatin Technologies offers a manufacturer copay savings card for commercially insured patients filling brand Vyleesi. Eligible patients may pay as little as $50 per fill, with the card covering the remaining copay up to a set annual maximum. The card is not valid for patients covered by any federal healthcare program, including Medicare, Medicaid, TRICARE, or Veterans Affairs benefits.

To activate the card, patients visit the Vyleesi website, complete an enrollment form, and receive a digital card that can be presented at any Idaho pharmacy. The annual benefit cap has historically been set at $6,000 to $7,200, sufficient to offset most of a year's worth of copays for patients whose insurance covers the drug at a specialty-tier level.

Patients without commercial insurance do not qualify for the copay card. For uninsured Idaho patients, the arithmetic is straightforward: compounded bremelanotide at $140 per month ($1,680 per year) costs less than two months of brand Vyleesi at list price.

Telehealth Access to Vyleesi in Idaho

Idaho permits telehealth prescribing of Vyleesi with no in-person visit requirement for the initial consultation. Idaho Code § 54-5707 defines a legitimate prescriber-patient relationship as one that can be established via real-time audio-video communication, and bremelanotide is not a controlled substance, so no additional DEA telemedicine registration is needed [7].

Several national telehealth platforms now serve Idaho patients for HSDD evaluation and bremelanotide prescribing. The typical workflow involves an intake questionnaire, a synchronous video visit with a licensed prescriber (physician, NP, or PA), and either an e-prescription to a local pharmacy or direct shipment from a partner compounding pharmacy.

Telehealth consultations for HSDD generally cost between $75 and $200 for the initial visit, with follow-up visits priced lower. Some platforms bundle the consultation fee into the medication cost when dispensing compounded bremelanotide.

For patients in rural Idaho, where the nearest sexual-medicine specialist may be hours away, telehealth represents a practical path to care. According to the U.S. Census Bureau's 2020 data, over 30% of Idaho's population lives in rural areas classified as health professional shortage areas [8].

Clinical Evidence Behind Bremelanotide

Bremelanotide received FDA approval in June 2019 based on the RECONNECT program, two replicate Phase 3 trials (Study 301 and Study 302) enrolling a combined 1,247 premenopausal women with HSDD [4]. Participants self-administered 1.75 mg bremelanotide subcutaneously on an as-needed basis over 24 weeks.

The results were statistically significant but modest in absolute terms. In Study 301, the bremelanotide group reported a mean increase of 0.5 satisfying sexual events per month compared to placebo. The Female Sexual Distress Scale (FSDS-DAO) desire domain score improved by a mean of -0.7 points versus placebo. Both co-primary endpoints reached their prespecified thresholds [4].

Nausea was the most common adverse event, occurring in approximately 40% of patients in the treatment arm versus 1% on placebo. About 13% of patients in the bremelanotide group discontinued due to nausea. The nausea tends to diminish with repeated dosing. Transient blood pressure elevation (systolic increase of 2 to 3 mmHg on average) was also observed, leading the FDA to include a precaution against use in patients with uncontrolled hypertension or known cardiovascular disease [1].

Dr. Anita Clayton, Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia and a RECONNECT investigator, stated in 2019: "The on-demand dosing model gives patients a degree of control over their treatment that daily medications do not offer. For the right patient, the benefit-to-risk ratio is favorable" [4].

A post-hoc analysis published in The Journal of Sexual Medicine found that treatment effects were consistent across age subgroups (18 to 30, 31 to 40, and 41 to 50) and were not influenced by baseline BMI [9]. This is relevant for Idaho's patient population, where the state's adult obesity rate was 33.4% in 2023 according to CDC behavioral risk factor data [10].

Comparing Your Options: Brand vs. Compounded vs. Flibanserin

Three pharmacotherapy options exist for Idaho women with HSDD. Here is how they stack up on cost and logistics:

Brand Vyleesi runs $1,200 per month at cash-pay, potentially $50 per fill with the manufacturer card and commercial insurance. It is on-demand dosing, requires subcutaneous injection, and comes in a proprietary autoinjector.

Compounded bremelanotide costs approximately $140 per month through a 503A pharmacy. Same active ingredient, same dose, same route. The trade-off is a standard syringe instead of an autoinjector and the absence of FDA manufacturing oversight on the final preparation.

Flibanserin (Addyi) is a daily oral tablet priced at roughly $400 to $500 per month without insurance, with generics potentially available. It requires daily adherence regardless of sexual activity frequency, carries an alcohol interaction warning, and the REMS program mandates prescriber certification [11]. Some patients prefer the on-demand flexibility of bremelanotide over daily dosing.

For an Idaho patient using the medication four to six times per month and lacking insurance coverage, compounded bremelanotide offers the strongest cost-to-benefit ratio.

Steps to Get Bremelanotide in Idaho at the Lowest Cost

A practical sequence for Idaho patients: schedule a telehealth consultation with a licensed prescriber experienced in HSDD ($75 to $200). If bremelanotide is appropriate, request a prescription written for compounded bremelanotide 1.75 mg subcutaneous injection, specifying a 503A compounding pharmacy that ships to Idaho. Fill the prescription at approximately $140 per month. If you have commercial insurance that covers Vyleesi, enroll in the Palatin Technologies savings card to reduce your copay to $50 or less per fill, then compare the net cost against the compounded option before deciding.